Approxima
is developing a novel treatment for patients with tricuspid valve regurgitation
Tricuspid regurgitation
Technology
Target the root cause of the pathology
Ventricle and annulus reshaping
(in-vivo data)
Tricuspid regurgitation reduction
(in-vivo data)
Quick and simple implantation procedure
IP protected in strategic geographies
Core team
Board
Scientific Board
News
Approxima will be presenting at LSI Europe23 Medtech Summit in September. We are looking forward to connecting with other innovators and experts in medtech industry in Barcelona.
Approxima closed a € 1.6M seed financing round for the development of its minimally invasive tricuspid valve repair technology and strengthens the team with both a new Chairman of the Board and a CMO. • The seed financing round was led by Panakès Partners alongside Club degli Investitori and a group of business angels. • […]
Approxima takes the stage at PCR London Valve 2023, the leading conference in transcatheter heart valve therapies, kicking off on Sunday, 19/11/2023.Approxima’s abstract has been handpicked by the Selection Committee as one of this year’s Top Innovations! Dr. Paolo will present our preclinical data for the first time in a public setting at the Top Innovations […]